Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer

被引:548
作者
van Meerbeeck, Jan P.
Kramer, Gijs W. P. M.
Van Schil, Paul E. Y.
Legrand, Catherine
Smit, Egbert F.
Schramel, Franz
Tjan-Heijnen, Vivianne C.
Biesma, Bonne
Debruyne, Channa
van Zandwijk, Nico
Splinter, Ted A. W.
Giaccone, Giuseppe
机构
[1] Ghent Univ Hosp, Dept Resp Med, B-9000 Ghent, Belgium
[2] Arnhem Radiotherapeut Inst, Dept Radiat Therapy, Arnhem, Netherlands
[3] Univ Hosp Antwerp, Dept Resp Med, Antwerp, Belgium
[4] Univ Hosp Antwerp, Dept Thorac Surg, Antwerp, Belgium
[5] European Org Res Treatment Canc, Ctr Data, Brussels, Belgium
[6] Vrije Univ Amsterdam, Dept Pulmonol, Amsterdam, Netherlands
[7] Vrije Univ Amsterdam, Dept Med Oncol, Amsterdam, Netherlands
[8] St Antonius Hosp, Dept Pulmonol, Nieuwegein, Netherlands
[9] Radboud Univ Nijmegen Med Ctr, Dept Med Oncol, Nijmegen, Netherlands
[10] Jeroen Bosch Ziekenhuis, Dept Pulmonol, Shertogenbosch, Netherlands
[11] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands
[12] Erasmus MC, Dept Pulmonol, Rotterdam, Netherlands
[13] Erasmus MC, Dept Med Oncol, Rotterdam, Netherlands
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2007年 / 99卷 / 06期
关键词
D O I
10.1093/jnci/djk093
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Induction chemotherapy before surgical resection increases survival compared with surgical resection alone in patients with stage IIIA-N2 non-small-cell lung cancer (NSCLC). We hypothesized that, following a response to induction chemotherapy, surgical resection would be superior to thoracic radiotherapy as locoregional therapy. Methods Selected patients with histologic or cytologic proven stage IIIA-N2 NSCLC were given three cycles of platinum-based induction chemotherapy. Responding patients were subsequently randomly assigned to surgical resection or radiotherapy. Survival curves were estimated using Kaplan-Meier analyses from time of randomization. Results Induction chemotherapy resulted in a response rate of 61% (95% confidence interval [Cl] = 57% to 65%) among the 579 eligible patients. A total of 167 patients were allocated to resection and 165 to radiotherapy. Of the 154 (92%) patients who underwent surgery, 14% had an exploratory thoracotomy, 50% a radical resection, 42% a pathologic downstaging, and 5% a pathologic complete response; 4% died after surgery. Postoperative radiotherapy was administered to 62 (40%) of patients in the surgery arm. Among the 154 (93%) irradiated patients, overall compliance to the radiotherapy prescription was 55%, and grade 3/4 acute and late esophageal and pulmonary toxic effects occurred in 4% and 7%; one patient died of radiation pneumonitis. Median and 5-year overall survival for patients randomly assigned to resection versus radiotherapy were 16.4 versus 17.5 months and 15.7% versus 14%, respectively (hazard ratio = 1.06, 95% Cl = 0.84 to 1.35). Rates of progression-free survival were also similar in both groups. Conclusion In selected patients with pathologically proven stage IIIA-N2 NSCLC and a response to induction chemotherapy, surgical resection did not improve overall or progression-free survival compared with radiotherapy. In view of its low morbidity and mortality, radiotherapy should be considered the preferred locoregional treatment for these patients.
引用
收藏
页码:442 / 450
页数:9
相关论文
共 41 条
[21]  
Liptay M J, 1999, Chest Surg Clin N Am, V9, P79
[22]   Morbidity and mortality after neoadjuvant therapy for lung cancer: The risks of right pneumonectomy [J].
Martin, J ;
Ginsberg, RJ ;
Abolhoda, A ;
Bains, MS ;
Downey, RJ ;
Korst, RJ ;
Weigel, TL ;
Kris, MG ;
Venkatraman, ES ;
Rusch, VW .
ANNALS OF THORACIC SURGERY, 2001, 72 (04) :1149-1154
[23]   Revisions in the International System for Staging Lung Cancer [J].
Mountain, CF .
CHEST, 1997, 111 (06) :1710-1717
[24]   Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer: an EORTC phase II study (EORTC 08958) [J].
O'Brien, MER ;
Splinter, T ;
Smit, EF ;
Biesma, B ;
Krzakowski, M ;
Tjan-Heijnen, VCG ;
Van Bochove, A ;
Stigt, J ;
Smid-Geirnaerdt, MJA ;
Debruyne, C ;
Legrand, C ;
Giaccone, G .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (10) :1416-1422
[25]   RANDOMIZED TRIAL OF NEOADJUVANT THERAPY FOR LUNG-CANCER - INTERIM ANALYSIS [J].
PASS, HI ;
POGREBNIAK, HW ;
STEINBERG, SM ;
MULSHINE, J ;
MINNA, J .
ANNALS OF THORACIC SURGERY, 1992, 53 (06) :992-998
[26]   Induction chemotherapy before surgery for early-stage lung cancer: A novel approach [J].
Pisters, KMW ;
Ginsberg, RJ ;
Giroux, DJ ;
Putnam, JB ;
Kris, MG ;
Johnson, DH ;
Roberts, JR ;
Mault, J ;
Crowley, JJ ;
Bunn, PA .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2000, 119 (03) :429-437
[27]   Complete resection in lung cancer surgery: proposed definition [J].
Rami-Porta, R ;
Wittekind, C ;
Goldstraw, P .
LUNG CANCER, 2005, 49 (01) :25-33
[28]  
Rami-Porta R, 2006, J THORAC ONCOL, V1, P605
[29]   A RANDOMIZED TRIAL COMPARING PREOPERATIVE CHEMOTHERAPY PLUS SURGERY WITH SURGERY ALONE IN PATIENTS WITH NON-SMALL-CELL LUNG-CANCER [J].
ROSELL, R ;
GOMEZCODINA, J ;
CAMPS, C ;
MAESTRE, J ;
PADILLE, J ;
CANTO, A ;
MATE, JL ;
LI, SR ;
ROIG, J ;
OLAZABAL, A ;
CANELA, M ;
ARIZA, A ;
SKACEL, Z ;
MORERAPRAT, J ;
ABAD, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (03) :153-158
[30]   A RANDOMIZED TRIAL COMPARING PERIOPERATIVE CHEMOTHERAPY AND SURGERY WITH SURGERY ALONE IN RESECTABLE STAGE IIIA NON-SMALL-CELL LUNG-CANCER [J].
ROTH, JA ;
FOSSELLA, F ;
KOMAKI, R ;
RYAN, MB ;
PUTNAM, JB ;
LEE, JS ;
DHINGRA, H ;
DECARO, L ;
CHASEN, M ;
MCGAVRAN, M ;
ATKINSON, EN ;
HONG, WK .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (09) :673-680